Selpercatinib (Retevmo)

Targeted TherapyApproved for: NSCLCBiomarker: RET Selpercatinib (Retevmo) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has a RET fusion gene and is metastatic. It is used in adults. Related Research News Lung Cancer Screening Expanded by...
|
May 27, 2021
|

Pralsetinib (Gavreto)

Targeted TherapyApproved for: NSCLCBiomarker: RET Pralsetinib (Gavreto) is approved for non-small cell lung cancer (NSCLC) that has a RET fusion gene and is metastatic. It is used in adults. Related Research News Lung Cancer Screening Expanded by MedicareLung Cancer...
|
February 25, 2021
|